News

Portraits of 2024 Amon Award winners

Meet the 2024 Amon Award Winners

MIT Koch Institute

The Koch Institute at MIT is pleased to announce the winners of the 2024 Angelika Amon Young Scientist Award, Anna Uzonyi and Lukas Teoman Henneberg. The prize was established in 2021 to recognize graduate students in the life sciences or biomedical research from institutions outside the United States who embody Dr. Amon’s infectious enthusiasm for discovery science. 



 

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Microfluidic device reveals leukemia cell behaviors in the blood

MIT Koch Institute

Scott Manalis and Michael Hemann published a new study in Communications Biology that improves our basic understanding of circulating leukemia cell dynamics over the course of disease progression and therapeutic response.

Understanding these circulation kinetics and clearance rates can inform our biological understandings of metastasis, as well as the design of tools that target these circulating cells for cancer diagnosis, treatment and monitoring.

Killian cancer at the nanoscale

MIT News

In her 2023-24 James R. Killian Jr. Faculty Achievement Award lecture, Paula Hammond showcased the layers that make up her mettle, from her childhood in Michigan, to her time as a student at MIT, and then her pioneering development of layer-by-layer nanomaterials for applications in cancer, medicine and energy.

Speeding up cancer gene screening

MIT News

The Sanchez-Rivera Lab devised a method to screen for the effects of cancer-associated genetic mutations much more easily and quickly than any existing approach. In a Nature Biotechnology study of lung cancer, researchers used a variant of CRISPR genome-editing called prime editing to screen cells with more than 1,000 different mutations of the tumor suppressor gene p53 observed in cancer patients. They found that some p53 mutations are more harmful than previously thought. The technique could one day be used to determine how an individual patient’s tumor will respond to a particular treatment.

This research was funded in part by the Koch Institute Frontier Research Program via the Casey and Family Foundation Cancer Research Fund, the Ludwig Center at MIT, and Upstage Lung Cancer.

Special delivery: Nanoparticles for RNA therapies

Proceedings of the National Academy of Sciences

Sangeeta Bhatia and Georgia Institute of Technology professor James Dahlman co-edited a special PNAS issue exploring nano-sized solutions for improving delivery of RNA therapeutics.

In addition to their introduction, other KI faculty highlights include:

Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system | Sangeeta Bhatia with Paula Hammond

Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies | Paula Hammond

Recent advances in nanoparticulate RNA delivery systems | Robert Langer and Daniel Anderson

New exhibits showcase trailblazing MIT women

MIT News

Featuring several KI faculty members, the exhibition, “Under the Lens: Women Biologists and Chemists at MIT 1865-2024,” will be on view in Hayden Library through June 21. Pictured from the accompanying digital exhibit: Margaret Hutchinson Rousseau (ScD ’37), the first woman to receive an ScD in Chemical Engineering, and the KI's own Paula Hammond ('83, PhD '93), fellow Course 10 alumna and first woman to head the Chemical Engineering Department.

Framework for vaccine success

MIT News

The Jaklenec Group designed a nanoparticle made from a metal organic framework (MOF) that both delivers vaccines and acts as an adjuvant to generate a strong immune response at a lower dose. In a study of mice appearing in Science Advances, the researchers showed that this MOF could successfully encapsulate and deliver part of the SARS-CoV-2 spike protein, while also acting as an adjuvant once the MOF is broken down inside cells.   

KI alum Viktor Adalsteinsson develops liquid biopsies to detect cancer

Slice of MIT

Cancer patients who undergo surgery are often left with a frightening question: Did the surgeons get all the cancerous cells? No one wants a recurrence of disease, but additional treatments such as radiation or chemotherapy have significant side effects. That’s why Viktor Adalsteinsson PhD ’15 has been developing tools to support better-informed treatment decisions: so-called “liquid biopsies” that can detect the presence of cancer from a simple blood test.

KI faculty take on Cancer Grand Challenges 

MIT News

Michael Birnbaum will lead Cancer Grand Challenges Team MATCHMAKERS, backed by $25 million over five years. Along with Regina Barzilay and Brandon DeKosky, the team will take advantage of recent advances in artificial intelligence to develop tools for personalized immunotherapies for cancer patients. In addition, Ömer Yilmaz will join team PROSPECT to help address early-onset colorectal cancers.

Early SOX knockout could score cancer win

MIT News

The Yilmaz and Jacks labs, with collaborators, have found that early in colon cancer development, cells that activate the SOX17 gene can become essentially invisible to the immune system. Further, blocking SOX17 may offer a new way to treat early-stage cancers before they progress, or aid prevention in patients prone to developing colon polyps.

This work was supported in part by the Bridge Project and the MIT Stem Cell Initiative.

Sharp Lab alum Albert Almada talks stem cells

MIT News

“Digging deep into the science is what MIT taught me." Albert Almada PhD ’13 talks about how his time in the Sharp Lab helped prepare him to ask new questions about how stem cells rebuild tissues.